On the contrary, there is a growing quantity of clinical trials, e.g., ficlatuzumab, which is a humanized HGF inhibitory monoclonal antibody preventing HGF/c-Met signaling by blocking the ligand-mediated activation which is actually in a phase 1b clinical trial for the treatment of non-small-cell lung cancer [56]. This evidence concerns the gene HGF and non-small cell lung carcinoma.